ADAR1 Capital Management, LLC 13F holdings, Q1 2025
Holdings as of March 31, 2025 · filings on SEC EDGAR · latest filing →
ADAR1 Capital Management, LLC disclosed 196 US equity positions worth $519.7m in its Q1 2025 13F filing. The largest position was PTGX at 8.7% of the reported book, followed by BOXX and ROIV. Against the Q4 2024 filing, it opened 6 new positions, added to 31 and reduced 9 among the top 50 holdings.
What did ADAR1 Capital Management, LLC own in Q1 2025? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2024 |
|---|---|---|---|---|---|---|---|
| 1 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 8.7% | $45.4m | 939,669 | -8% | reduced |
| 2 | BOXX EA SERIES TRUST | 7.2% | $37.6m | 337,125 | 4% | added | |
| 3 | ROIV ROIVANT SCIENCES LTD | Healthcare | 6.8% | $35.1m | 3,483,404 | -1% | reduced |
| 4 | ZLAB ZAI LAB LTD | Healthcare | 6.5% | $34.0m | 940,858 | -10% | reduced |
| 5 | IMVT IMMUNOVANT INC | Healthcare | 3.2% | $16.6m | 968,866 | 23% | added |
| 6 | CYTK CYTOKINETICS INC | Healthcare | 3.0% | $15.7m | 390,729 | -6% | reduced |
| 7 | KROS KEROS THERAPEUTICS INC | Healthcare | 2.9% | $15.1m | 1,486,461 | 6294% | added |
| 8 | ABVX ABIVAX SA | 2.7% | $13.8m | 2,210,019 | 46% | added | |
| 9 | BIL SPDR SER TR | 2.4% | $12.4m | 135,585 | 3% | added | |
| 10 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 2.3% | $11.7m | 339,635 | -50% | reduced |
| 11 | IKT INHIBIKASE THERAPEUTICS INC | 2.2% | $11.2m | 5,122,105 | 0% | held | |
| 12 | SWTXUSD SPRINGWORKS THERAPEUTICS INC | 1.8% | $9.2m | 207,778 | – | new | |
| 13 | SHY ISHARES TR | 1.6% | $8.5m | 103,337 | – | new | |
| 14 | TEVA TEVA PHARMACEUTICAL INDS LTD | Healthcare | 1.5% | $8.1m | 523,767 | 257% | added |
| 15 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 1.5% | $7.8m | 122,921 | 207% | added |
| 16 | PERCEPTIVE CAP SOLUTIONS COR | 1.5% | $7.7m | 750,000 | 0% | held | |
| 17 | CGON CG ONCOLOGY INC | Healthcare | 1.4% | $7.4m | 301,134 | 40% | added |
| 18 | RAPT THERAPEUTICS INC | 1.4% | $7.3m | 5,970,768 | 408% | added | |
| 19 | ABUS ARBUTUS BIOPHARMA CORP | Healthcare | 1.3% | $6.6m | 1,879,114 | 21% | added |
| 20 | ITCIEUR INTRA-CELLULAR THERAPIES INC | 1.2% | $6.3m | 48,044 | – | new | |
| 21 | RVMD REVOLUTION MEDICINES INC | Healthcare | 1.2% | $6.3m | 177,136 | 4% | added |
| 22 | AVR ANTERIS TECHNOLOGIES GLOBAL | 1.2% | $6.1m | 1,678,063 | 59% | added | |
| 23 | AA MISSION ACQUISITION CORP | 1.2% | $6.0m | 578,359 | 3% | added | |
| 24 | SG7 SAGE THERAPEUTICS INC | 1.1% | $5.9m | 742,495 | 3767% | added | |
| 25 | ETNBGBP 89BIO INC | 1.1% | $5.8m | 804,220 | 56% | added | |
| 26 | COHERUS BIOSCIENCES INC | 1.1% | $5.5m | 5,625,000 | 0% | held | |
| 27 | OAKTREE ACQUISITION CORP III | 1.0% | $5.4m | 516,482 | 3% | added | |
| 28 | HELIX ACQUISITION CORP II | 1.0% | $5.3m | 469,729 | 16% | added | |
| 29 | AMLX AMYLYX PHARMACEUTICALS INC | Healthcare | 1.0% | $5.2m | 1,471,587 | – | new |
| 30 | SRRK SCHOLAR ROCK HLDG CORP | Healthcare | 1.0% | $5.1m | 157,079 | 705% | added |
| 31 | XENE XENON PHARMACEUTICALS INC | Healthcare | 0.8% | $4.3m | 127,548 | 152% | added |
| 32 | XNCR XENCOR INC | Healthcare | 0.8% | $4.2m | 398,152 | 70% | added |
| 33 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 0.8% | $4.2m | 263,425 | -69% | reduced |
| 34 | SEPN SEPTERNA INC | 0.8% | $4.2m | 720,848 | – | new | |
| 35 | JANX JANUX THERAPEUTICS INC | Healthcare | 0.8% | $4.2m | 153,767 | 388% | added |
| 36 | BBIO BRIDGEBIO PHARMA INC | 0.8% | $4.0m | 4,500,000 | 0% | held | |
| 37 | APGE APOGEE THERAPEUTICS INC | Healthcare | 0.8% | $3.9m | 104,853 | 154% | added |
| 38 | SVRA SAVARA INC | Healthcare | 0.7% | $3.8m | 1,360,291 | 38% | added |
| 39 | MNPR MONOPAR THERAPEUTICS INC | 0.7% | $3.7m | 100,774 | -23% | reduced | |
| 40 | AEROVATE THERAPEUTICS INC | 0.7% | $3.7m | 1,461,234 | 57% | added | |
| 41 | BIOA BIOAGE LABS INC | 0.7% | $3.7m | 971,100 | 689% | added | |
| 42 | ZURA ZURA BIO LTD | Healthcare | 0.7% | $3.6m | 2,801,184 | 35% | added |
| 43 | CATBUSD ASTRIA THERAPEUTICS INC | 0.7% | $3.4m | 641,690 | 605% | added | |
| 44 | RZLT REZOLUTE INC | 0.6% | $3.2m | 1,116,047 | -18% | reduced | |
| 45 | CNTA CENTESSA PHARMACEUTICALS PLC | 0.6% | $3.1m | 216,166 | 40% | added | |
| 46 | AKERO THERAPEUTICS INC | 0.6% | $2.9m | 71,143 | 365% | added | |
| 47 | MERUS N V | 0.5% | $2.8m | 66,960 | -18% | reduced | |
| 48 | BRIDGEBIO PHARMA INC | 0.5% | $2.7m | 2,666,627 | – | new | |
| 49 | PTCT PTC THERAPEUTICS INC | Healthcare | 0.5% | $2.5m | 50,023 | 4% | added |
| 50 | RGNX REGENXBIO INC | Healthcare | 0.5% | $2.5m | 350,352 | 106% | added |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.